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HEART PILLS ARE RED, VIAGRA IS BLUE...
WHEN DOES PILL COLOR BECOME
FUNCTIONAL? AN ANALYSIS OF UTILITARIAN
AND AESTHETIC FUNCTIONALITY AND THEIR
UNINTENDED SIDE EFFECTS IN THE
PHARMACEUTICAL INDUSTRY
Signe H. Naevet
Abstract
As consumers, we often associate pill color and shape with
particular medications. Should that trade dress be protected beyond
the expiration of the patent? Legal scholars have recognized some of
the tensions and inconsistencies in court opinions when it comes to
trade dress protection for pill shape and color. This article focuses on
the specific tensions between requiring secondary meaning and non-
functionality, as well as the potential of "genericide" when generic
pharmaceuticals enter the market. Ultimately this article makes some
novel recommendations to assess functionality at the time of FDA
approval for the pharmaceutical and to have the FDA responsible for
determining when a shape and color should be an industry standard,
creating an exception to trade dress protection. Some exceptions for
allowing protection for pill shape and color could be for flavor and
colors that indicate flavor, for medications that indicate dosage, or
for medications that are associated with a particular patient
compliance or psychosomatic effect.
INTRODUCTION
Imagine a world without the little blue pill or the purple pill. For
pharmaceuticals, colors and shapes not only signify the type of
medication to a consumer, they can also represent the source of each
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medication. Most consumers would identify a shiny, round, brown
pill not just as an anti-inflammatory medication or even as Ibuprofen,
but as Advil. "The purple pill" is Nexium and the light blue angular
pill, Viagra. Relying on trade dress to protect the pill color and shape
after the patent term has expired enables the manufacturer to extend
its market power via another form of intellectual property protection.
Like most medications, however, trade dress protection can have
unintended side effects.
To obtain trade dress protection for shape and color, the design
cannot be functional and the owner must demonstrate that it has
acquired secondary meaning in the minds of consumers. A problem
arises because, as the brand owner develops secondary meaning in the
trade dress, the color and shape can begin to cross the line into
functionality, which would then exclude it from protection. "The
purple pill" not only signifies the brand Nexium, but it also identifies
the pill for acid reflux. In other cases, a shape or color may become
associated with a particular dosage, efficacy, result or soothing effect.
Sometimes an element of the medication that was not "functional" in
its original design begins to serve a purpose over time and the
manufacturer is now potentially a victim of its own success.
Additionally, a form of trade dress "genericide" has the potential of
occurring to allow generic drugs to enter the market.
This article will first briefly explain the history of trademark and
trade dress protection for color and shape. Second, it will introduce
the functionality limitations that have arisen in relation to pill shape
and color and introduce the concept of aesthetic functionality. Third,
it will consider public interest considerations that justify allowing or
disallowing protection. Fourth, it will examine more deeply the
protection that has been afforded pill shape and color and assess
whether trade dress protection is being preempted in the
pharmaceutical context due to functionality, aesthetic functionality,
and genericness concerns.
Ultimately, this article will argue that color and shape should not
become functional or be subject to genericide as a result of creating
secondary meaning; that substitution for generic drugs should not be a
reason to find that a color and/or shape are functional or generic; that
functionality could be determined when the color and/or shape are
adopted, not at the time of assessing secondary meaning; that using
color and/or shape to indicate a general type of medication should not
be considered functional, unless they are industry-regulated by the
FDA; that using industry-accepted color and/or shape to indicate
dosage is an acceptable functionality limitation, but it too should be
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regulated by the FDA; and finally that flavor and colors that indicate
flavors should be considered functional due to scarcity concerns.
I. TRADEMARK AND TRADE DRESS PROTECTION FOR COLOR AND
SHAPE
A. Trademark Protection for Color
Under United States trademark law, it is possible for non-
traditional source indicators, such as color,' taste, 2 sound,3 and smell 4
to qualify for trademark protection.5 Prior to 1995, there was a circuit
split regarding the protection available for colors as trademarks.6 This
split was resolved with the landmark case, Qualitex v. Jacobson
Products.7 In Qualitex, the Supreme Court held that there was no
special rule preventing color from serving a trademark function, and
hence color was not per se prohibited from protection. Accordingly,
the greenish-gold color of the dry cleaning press pads at issue in the
case could be registered for trademark protection.9 Qualitex thus
resolved an earlier debate and opened the door for trademark
protection for colors.
Two of the main arguments addressed by the Court in Qualitex
were the fear of shade confusion and color depletion.10 Jacobson
argued that if color were a permissible trademark, there would be
uncertainty as to permissible shades and courts would constantly be
forced to resolve disputes about lawful and unlawful uses of color.I
How can we tell the difference between sky blue and light blue? The
Court rejected the shade confusion argument reasoning that color
disputes were no different from any of the other likelihood of
1. See generally Qualitex Co. v. Jacobson Prods. Co., Inc., 514 U.S. 159 (1995) (holding
green-gold color for dry cleaning press pads registerable; no per se exclusion to registration of
color).
2. See In re N.V. Organon, 79 U.S.P.Q.2d 1639 (T.T.A.B. 2006) (rejecting orange
flavor for medication as trademark, placing flavor with color and product design as non-
inherently distinctive).
3. See In re Gen. Elec. Broad. Co., Inc., 199 U.S.P.Q. 560 (T.T.A.B. 1978) ("Ship's Bell
Clock" registerable if could show acquired distinctiveness).
4. See In re Clarke, 17 U.S.P.Q.2d 1238 (T.T.A.B. 1990) (plumeria flower fragrance on
sewing thread and embroidery yarn registerable).
5. This article will not address trademark protection for sound or smell.
6. See Qualitex, 514 U.S. at 161.
7. See id.
8. See id. at 164.
9. See id. at 174,
10. See id. at 167-68.
11. See id. at 167.
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confusion analyses that courts undergo on a regular basis. 12 Jacobson
also argued that colors are in limited supply and competitors would be
placed at a disadvantage if suitable colors were unavailable." The
Court also rejected this argument reasoning that the rare circumstance
where color scarcity might be a concern did not warrant a blanket
prohibition against allowing trademark protection for color.14 These
arguments continue to have relevance as color has been applied in the
pharmaceutical context.
B. Trademark and Trade Dress Protection for Shape
Protection for shape is more appropriately addressed under trade
dress protection, a recognized subset of trademark protection for
product packaging and design. Trade dress includes the product's
packaging and its independent appearance.15 Famous examples of
trade dress include the distinctive Robin's egg blue bags and boxes
with the white satin ribbons used by Tiffany and Co.16 and the yellow
arches and red and yellow d6cor of McDonald's restaurants.' 7 Courts
have actually separated trade dress into at least two different
categories-product packaging and product design-and have created
a legal distinction between the two.
1. Product Packaging
In Two Pesos v. Taco Cabana,'8 the Supreme Court considered
the protectability of a Mexican restaurant's brightly colored d6cor.
The Court addressed whether trade dress for d6cor would fall on the
traditional Abercrombie' 9 spectrum of distinctiveness. Along the
Abercrombie spectrum, trademarks that are generic will receive no
protection, trademarks that are descriptive can receive protection only
if secondary meaning is shown, and trademarks that are suggestive,
arbitrary or fanciful can receive protection without a showing of
12. See id
13. See id. at 168.
14. See id.
15. See William T. Fryer, Trademark Product Appearance Features, United States and
Foreign Protection Evolution: A Need for Clarification and Harmonization, 34 J. MARSHALL L.
REv. 947, 948 (2001) (discussing functionality and trade dress protection).
16. See U.S. Registration No. 2416794 (claiming date of first use of 1939).
17. See, e.g., Our History, McDonalds,
http://www.mcdonalds.com/us/en/our-story/our-history.html (last visited Oct. 14, 2010).
18. Two Pesos, Inc. v. Taco Cabana, Inc., 505 U.S. 763 (1992).
19. Abercrombie & Fitch Co. v. Hunting World, Inc., 537 F.2d 4 (2d Cir. 1976).
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secondary meaning. Suggestive, arbitrary, and fanciful marks are
considered to be "inherently distinctive," hence requiring no
additional proof of distinctiveneSS21 whereas trademarks that are
descriptive require extra proof before they will be awarded
22
protection.22 The Two Pesos Court held that the restaurant's d6cor
was possible of being inherently distinctive and hence no showing of
secondary meaning would be required before protection could be
awarded.23
2. Product Design
In Wal-Mart v. Samara Brothers,24  however, the Court
addressed distinctiveness for product appearance and held that
"product design" was not inherently distinctive. 25 The Court drew this
reasoning from some dicta in Qualitex, which stated that color could
never be inherently distinctive.26 The Wal-Mart case involved seer-
sucker patterned children's clothing rather than restaurant d6cor. The
Court accordingly drew a distinction between product packaging, like
the restaurant d6cor in Two Pesos, and product design, like the
children's clothing in Wal-Mart.2 7 The Court said that product
packaging could be inherently distinctive whereas product design
could not. 28 As a result, product packaging does not require a
showing of secondary meaning whereas product design does. If in
doubt, the Court advised to favor a finding of product design,
requiring a showing of secondary meaning.29 Pill shape and color are
considered product design, so, like the clothing in Wal-Mart,
secondary meaning is required.o
20. See id at 9.
21. See id at 9-10.
22. See id.
23. See Two Pesos, 505 U.S. at 776.
24. Wal-Mart Stores, Inc. v. Samara Bros., Inc., 529 U.S. 205 (2000).
25. Id. at 215.
26. Id. at 211-12 (citing Qualitex, 514 U.S. at 162-63). See also Fryer, supra note 15, at
955 (discussing trade dress cases).
27. See David E. Shipley, What do Flexible Road Signs, Children's Clothing and the
Allied Campaign in Europe during WWI have in Common? The Public Domain and the
Supreme Court's Intellectual Property Jurisprudence, 13 U. BALT. INTELL. PROP. L.J. 57, 71
(2005) (noting that the Wal-Mart decision was justified to protect competition and consumer
interests).
28. See Wal-Mart, 529 U.S. at 212-13.
29. See id at 215.
30. See, e.g., Inwood Lab., Inc. v. Ives Lab., Inc., 456 U.S. 844, 857 (1982).
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II. SECONDARY MEANING AND FUNCTIONALITY LIMITATIONS FOR
SHAPE AND COLOR
A. Secondary Meaning
To obtain trademark protection for non-traditional source
indicators, such as color, shape, and trade dress product design,
therefore, it is necessary to show secondary meaning.3' These features
are considered not to be inherently distinctive and must acquire an
association in the minds of the consumer to obtain protection. 32 In
order to surpass the secondary meaning threshold and to acquire
distinctiveness, the mark holder must contribute a significant
investment in marketing to create the association between the
products and its source in the minds of consumers.33 Evidence to
support secondary meaning can include surveys, affidavits, extensive
advertising, focused advertising, success of sales, copying by
competitors, and long exclusivity of use. 34 For the purple pill, this
meant $41.9 million in marketing efforts in 1997.3s This number had
grown to $107.9 million by 2000.36
B. Utilitarian Functionality
In addition to secondary meaning, the color and shape must be
non-functional.3 7 The USPTO defines functionality as an element that
is "essential to the use or purpose of the article or if it affects the cost
or quality . ... "" Competitive need is also a significant
consideration, although it is not determinative.39  Traditional
31. See I J. THOMAS MCCARTHY, MCCARTHY ON TRADEMARKS AND UNFAIR
COMPETITION, § 7:44 (4th ed. 2006).
32. See U.S. PAT. & TRADEMARK OFFICE, U.S. DEP'T OF COMMERCE, TRADEMARK
MANUAL OF EXAMINING PROCEDURE §§ 1202.05, 1212 (7th ed., 2010) [hereinafter TMEP].
33. See RESTATEMENT (THIRD) OF UNFAIR COMPETITION § 13 (1995).
34. See generally David E. Rigney, Annotation, Application of secondary meaning test in
action for trade dress infringement under § 43(a) of Lanham Act (15 US.C.A. § 1125(a)), 87
A.L.R. FED. 15 (1988).
35. David M. Fritch, Should "The Purple Pill" by Any Other Drug Company Still be as
Purple? The Changing Face of Trade Dress Protection for Pharmaceutical Manufacturers, 47
IDEA 171, 188 (2006) (citing RICHARD FRANK ET AL., KAISER FAMILY FOUNDATION, TRENDS
IN DIRECT-TO-CONSUMER ADVERTISING OF PRESCRIPTION DRUGS Exhibit 6 (2002), available
at http://www.kff.org/rxdrugs/loader.cfm?url=/commonspot/security/getfile.
cfm&PagelD=14881).
36. Id
37. See TMEP, supra note 32, § 1202.02(a)(111)(A).
38. Id. § 1202.02(a) (citing TrafFix Devices, Inc. v. Marketing Displays, Inc., 532 U.S.
23, 33, 58 U.S.P.Q.2d 1001, 1006 (2001)).
39. Id. § 1202.02(a)(v)(C) (citing Valu Engineering, Inc. v. Rexnord Corp., 278 F.3d
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utilitarian functional features are ones that "insure 'practical operation
of the article,' or [ ] promote efficiency for the purpose to which it is
devoted, or [ ] secure[s] the excellence or functional perfection of the
product; and/or is for the sake of economy, e.g. to reduce the cost of
manufacture." 4 0 According to the Chicago school of economics, a
feature is functional if it would be costly to design around or it would
be found in most brands, even when deception is not a goal.4 1
To determine functionality normally requires an assessment of
the Morton-Norwich4 2 factors: "(1) the existence of a utility patent
that discloses the utilitarian advantages of the design sought to be
registered; (2) advertising by the applicant that touts the utilitarian
advantages of the design; (3) facts pertaining to the availability of
alternative designs; and (4) facts pertaining to whether the design
results from a comparatively simple or inexpensive method of
manufacture."43 These factors are not individually determinative,4 4
but they generally point to the useful aspects of the feature: was it
useful enough that it was awarded a patent? Is this an essential
feature, and was it emphasized in product advertising? Could a
competitor have adopted a different design or would a design-around
be cost prohibitive and anti-competitive?
These factors allude to the traditional line that functionality
draws between trade dress protection and patent protection.45 Thus, in
TrafFix Devices v. Marketing Displays,4 6 road signs with a dual
spring design, which previously had been covered by a utility patent,
were not eligible for trade dress protection.47 Another example
involving traffic signs is the functional advantage to using yellow or
orange for safety signs.4 8 Because colors serve a functional purpose,
to aid with safety, one company cannot monopolize them.
1268, 1277 (Fed. Cir. 2002)).
40. 3 Louis ALTMAN & MALLA POLLACK, CALLMANN ON UNFAIR COMPETITION,
TRADEMARKS AND MONOPOLIES § 19:8 (4th ed. 2010) [hereinafter CALLMANN] (discussing
functionality for utilitarian features).
41. See id.
42. In re Morton-Norwich Prods., Inc., 671 F.2d 1332, 1340 (C.C.P.A. 1982).
43. TMEP, supra note 32, § 1202.02(a)(v) (citing Morton-Norwich, 671 F.2d at 1340-
41).
44. See id § 1202.02(a)(v).
45. See Shipley, supra note 27, at 58.
46. TrafFix Devices, Inc. v. Mktg. Displays, Inc., 532 U.S. 23 (2001).
47. See id. at 35.
48. See TMEP, supra note 32, § 1202.05(b) (citing Saint-Gobain Corp. v. 3M Co., 90
U.S.P.Q.2d 1425, 1447 (T.T.A.B. 2007) (finding deep purple shade for coated abrasives
functional)).
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Accordingly, functionality separates the scope of intellectual property
protection and is a dividing line for whether trade dress protection is
available.4 9
C. Aesthetic Functionality
The TrajFix case actually articulates two tests for functionality.
In addition to the traditional test, whether the feature is essential to
the use or purpose or affects the cost or quality, the case also
identified a second test, whether a feature's exclusive use would put
competitors at a significant, non-reputation-related, disadvantage.50
This second test is often referred to as "aesthetic functionality."51
Thus, independent from utilitarian functionality, a feature may be
functional if competitors need it to compete for reasons other than
building upon a competitor's goodwill. In the context of color,
aesthetic functionality is a companion to utilitarian functionality,
"where the evidence indicates that the color at issue provides specific
competitive advantages that, while not necessarily categorized as
purely 'utilitarian' in nature, nevertheless dictate that the color
remains in the public domain." 5 2 A feature that is aesthetically
functional thus makes the product more pleasing or attractive in some
regard. 53
D. Color and Functionality
Courts have recognized an interesting relationship between color
and functionality, including aesthetic functionality. Prior to the
Qualitex decision, the Federal Circuit addressed trademark protection
for color and color scarcity, and awarded protection for the color pink
in fibrous insulation.54 Essentially the Federal Circuit collapsed the
color scarcity and functionality arguments into one consideration. In
a two-to-one decision, the Federal Circuit ruled in favor of Owen-
49. See Fryer, supra note 15, at 957. Note that a similar line is drawn in copyright with
useful articles and the idea/expression dichotomy.
50. See CALLMANN, supra note 40, § 19:8 (citing Tra/Fix, 532 U.S. at 33).
51. See TrafFix, 532 U.S. at 33 (citing Qualitex, 514 U.S. at 170).
52. TMEP, supra note 32, § 1202.05(b) (citing Brunswick Corp. v. British Seagull Ltd.,
35 F.3d 1527, 1533 (Fed. Cir. 1994, cert. denied, 514 U.S. 1050 (1995)).
53. See Fryer, supra note 15, at 964; Qualitex, 514 U.S. at 166 (For example, it was
argued that the press pad color may make the product more attractive because it would conceal
stains). See also Deere & Co. v. MTD Holdings Inc., 70 U.S.P.Q.2d 1009 (S.D.N.Y. 2004)
(stating farm equipment could be in green and yellow for aesthetic functionality reasons,
although Deere could protect its specific green and yellow combination).
54. See In re Owens-Coming Fiberglas Corp., 774 F.2d 1116 (Fed. Cir. 1985).
55. See I MCCARTHY, supra note 31, § 7:42.
2011] HEART PILLS ARE RED, VIAGRA IS BLUE ...
Coming and its Pink Panther insulation campaign, determining that
the color pink was not precluded from registration. Significantly,
the court said that "pink has no utilitarian purpose and does not
deprive competitors of any reasonable right or competitive need."57
Owens-Coming had devoted extensive resources in its Pink Panther
advertising campaign in an effort to get consumers to make the
connection with its product and purchase the pink insulation.
Pink was an arbitrary selection; it was not necessary for the
functioning of the insulation. Any other color would have worked
equally well and insulation is rarely seen by anyone other than the
person installing it. Furthermore, there was no competitive need for
another company to use pink, unless others were trying to free-ride on
the goodwill that had been created by Owens-Coming. This is
particularly true of a product like insulation that is identifiable when
purchasing it, but does not need to match with other insulation.
Qualitex took the "Pink Panther" case one step further and
recognized functionality as a limitation that could help to resolve the
color scarcity debate. Color scarcity had previously been viewed by
several circuits as a reason for a per se limitation against allowing
trademark protection for color.60 Qualitex recognized that policy
reasons did not justify a per se limitation on color, but in reaching this
conclusion the Court seemed to find some solace in the outer bounds
of functionality. The Court reasoned that if a color depletion or color
scarcity problem were to arise, that "the trade mark doctrine of
'functionality' normally would seem available to prevent the
anticompetitive consequences . ,,6 1 For example, the Qualitex
Court recognized previous determinations involving some limitations
relating to color, such as the color green and yellow for farm
equipment because purchasers might want their equipment to match;
the color black for outboard motors because it made the motors
appear smaller and ensured compatibility; and the color blue for
fertilizer because the scientific community recognized blue to signify
nitrogen. 62 Thus, functionality could step in where color scarcity
leaves off.
56. Id.
57. Id. (quoting Owens-Corning, 774 F.2d at 1122).
58. See Owens- Corning, 774 F.2d at 1126-27.
59. See I MCCARTHY, supra note 31, § 7:44.
60. See, e.g., NutraSweet Co. v. Stadt Corp., 917 F.2d 1024, 1028 (7th Cir. 1990)
(holding absolute prohibition for protection of color).
61. Qualitex, 514 U.S. at 169.
62. See id. See also I MCCARTHY, supra note 31, § 7:44.50.
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E. Genericide, Functionality, and Trade Dress
The role that functionality plays in trade dress protection in some
aspects parallels the role of generic trademarks. Under traditional
trademark jurisprudence, a term would be considered generic, and
hence not inherently distinctive and not entitled to legal protection, if
63it represented the genus rather than the species of a good. For
example, the word "table" on its own could never serve as the
trademark for a table. Moreover, a term that originally had a distinct
meaning, but over time becomes commonly accepted as the genus
rather than the species of a good, can suffer a fate known as
genericide. One example is the "Murphy bed case."" The genus was
a bed that folds down from the wall. The species was the "Murphy
bed." Unfortunately for the original manufacturers of the "Murphy
bed," it became the commonly accepted term for a bed that folds
down from the wall, so they could no longer monopolize "Murphy
bed" as a trademark.
Genericness for trade dress is similar in concept, but slightly
different in scope from generic trademarks like the "table" example.
As one court has summarized, there are three basic categories of
generic trade dress: (1) a design that is an overbroad or generalized
theme or style of doing business; (2) a design that has such a basic or
necessary format that no one should have a monopoly; and (3) a
design that is so common in an industry that it is incapable of
identifying any particular source. For example, "packaging lime-
flavored soda in green twelve-ounce cans is so common in the soft
drink industry that such packaging probably is not inherently
distinctive, although without the industry practice green cans would
be either suggestive or arbitrary and therefore inherently
distinctive." 66 Likewise, one court determined that a rectangular
shortbread cookie diagonally dipped in chocolate is a generic cookie
63. See A.J. Canfield Co. v. Honickman, 808 F.2d 291, 305-06 (3d Cir. 1986).
64. Murphy Door Bed. Co. v. Interior Sleep Sys., Inc., 874 F.2d 95,101 (2d Cir. 1989).
65. See Big Island Candies, Inc. v. The Cookie Corner, 269 F. Supp.2d 1236, 1243-44 (D.
Hawaii 2003).
66. The Paddington Corp. v. Attiki Imps. & Distribs., Inc., 996 F.2d 577, 583-84 (2d Cir.
1993) (comparing product packaging for Ouzo bottles and upholding distinctiveness under Two
Pesos). See also Deborah F. Buckman, Annotation, When is trade dress "inherently distinctive"
for purposes of trade dress infringement actions under § 43(a) of Lanham Act (15 US C.A.
§ 1125(a)) - Cases after Two Pesos, 161 A.L.R. FED. 327, 342 (2000); Fun-Damental Too,
Ltd. v. Gemmy Indus. Corp., Ill F.3d 993 (2d Cir. 1997) (holding district court did not err in
finding that collective features of packaging for toy bank shaped like toilet was inherently
distinctive, even if individually elements were not).
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design and would be unprotectable.67 Although these examples fall
under the generic category, the reasoning for forbidding generic
designs68 in trade dress echoes some of the previously discussed
functionality concerns, in particular the ability to compete and
aesthetic functionality.
Similarly, when a patent expires and that patent determines the
shape and manufacture of the good, then that shape and manufacture
may fall into the public domain. In a 1938 case before the Supreme
Court, the Kellogg Company sought to protect a trademark for
"Shredded Wheat" as well as trade dress protection for the square
pillow shape of its shredded wheat cereal. 6 9 The Court upheld the
conclusion that "shredded wheat" was descriptive of the product.70
For this and other reasons the Court would not allow Kellogg to
maintain a monopoly over the term.7 Regarding the cereal shape, the
Court was influenced by the fact that the patented device that created
the cereal had expired and hence the technology had fallen into the
public domain.72 The technology covered by the patent dictated the
form of the cereal and hence the form, like the patent, had also fallen
into the public domain.73 If the Court reached a different conclusion,
the public would not be able to practice the expired patent, so the
Court denied trade dress protection.
III. PUBLIC INTEREST CONCERNS
While pharmaceutical companies may have valid reasons for
wanting trade dress protection for pill shape and color, public interest
concerns in some instances weigh in favor of that protection and in
some instances weigh against protection. This section will highlight
some of those public interest concerns.
67. See Big Island Candies, 269 F. Supp.2d at 1247-48.
68. Note that these cases were actually packaging, not design cases. The courts were not
assessing secondary meaning, but rather were seeking to determine whether the design of the
packaging was inherently distinctive after Two Pesos. Although both the Paddington and the
Fun-Damental cases upheld the lower courts' findings that the packaging was distinctive, in
both instances the Second Circuit noted that packaging that was industry standard would not be
protected.
69. See Kellogg Co. v. Nat'l Biscuit Co., 305 U.S. 111 (1938).
70. See id. at 116.
71. Seeid.atll6-17.
72. See id. at 119-20.
73. Id. at 120.
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A. Ability to Identify Medication
Pills potentially have several different "consumers." Each of
these consumers has their own concerns with regard to identifying the
medication. The first consumer, a doctor, nurse, or pharmacist, will
want to ensure that he is prescribing and/or dispensing the proper
medication to the patient. 74 Once the packaging is removed, the pill
color and shape may be the last line of defense as it still serves the
purpose of identifying the medication and potentially minimizing
errors. 75 Allowing protection for a unique trade dress would further
these goals. If the doctor or pharmacist supports the substitution of
generic medications, however, then allowing the same trade dress for
both the pioneer as well as the generic drugs would further that goal.
The second consumer is the patient. The patient may want the
generic substitution for cost reasons,7 6  but would like the
psychological reassurance that the new medication is the same as the
original.77 Allowing the same color and shape combinations may
increase patient compliance in this regard. Furthermore, the patient
may become familiar with a certain color or shape representing a
certain type of medication or they mix medications in the same
container and then rely upon visual cues to identify the medication. 79
In contrast, the patient may want assurance that the pill is the same
that she has taken successfully in the past, and that it has not been
substituted by a generic version. Permitting trade dress protection for
the original would assure this clarity. Allowing only one true provider
for a drug with a distinct trade dress may also assist with countering
74. See, e.g., James A. Thomas, The Errors of Error Testing: Potential Liability issues
for Medication Error Testing of Pharmaceutical Trademarks under U.S. Law, 59 FooD DRUG
L.J. 325, 327 (2004) (describing error testing for medications and mistakes that can occur
because of trademarks that are close in name).
75. See Kevin J. McGough, Reassessing the Protectibility ofPrescription and OTC Drug
Trade Dress, 81 TRADEMARK REP. 255, 255-56 (1991); Darrel C. Karl, "Look-alike" Capsules,
Generic Drug Substitution, and the Lanham Act: The Elusive Contributory Infringement
Standard of Inwood Lab., Inc. v. Ives Lab., Inc., 32 CATH. U.L. REv. 345, 347 (1982) (noting
that similar drug colors can facilitate illegal substitution).
76. See Karl, 32 CATH. U. L. REv. at 345 (noting that generic substitution laws favor
competitive pricing); see also Melissa K. Davis, Comment, Monopolistic Tendencies ofBrand-
Name Drug Companies in the Pharmaceutical Industry, 15 J.L. & CoM. 357, 365 (1995).
77. Daniel R. Bereskin, Brand Name and "Look-Alike" Drugs in Canada after Ciba-
Geigy v. Apotex: A Proposalfor Relieffrom Slavish Imitation, 94 TRADEMARK REP. 1086, 1087
(2004) (citing to arguments presented by generic companies); see also infra Part IV.C
(discussing psychosomatic effect and patient compliance).
78. Id.
79. Id
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counterfeits.so
The third potential consumer is the hospital or emergency
responder. Consistency in pill shape and color for medications and/or
dosages could assist emergency personnel when responding to an
emergency situation, especially if the patient is unconscious or
otherwise unable to communicate. This argument would support
consistency in pill shape and color and not support trade dress
protection.
B. Bioequivalence
Similarly, the issue of bioequivalence contains public interest
concerns that can cut both ways. There is debate about whether two
different formulas can ever really be bioequivalent because some
patients react differently to filler ingredients, even when the active
ingredients are consistent.8 ' The only way to make sure that a patient
is taking the exact same medication is to not allow substitution.
Because similar trade dress can assist or accidentally lead to
substitution, requiring different trade dress can alleviate concerns
regarding bioequivalence. In contrast, if a drug truly is
bioequivalent,8 2 some would argue that substitution should be
allowed and that using the same shape and color would assist with
substitution and patient compliance.
C. Generic Substitution
One of the public interest arguments in favor of allowing the
same pill shape and color for pioneers as well as generics is to support
patient compliance with generic substitutions. 83 The Hatch-Waxman
Act8 4 is a strong policy statement in favor of generics experiencing a
smooth entry into the marketplace. It allows development and clinical
80. See generally Merri C. Moken, Comment, Fake Pharmaceuticals: How They and
Relevant Legislation or Lack Thereof Contribute to Consistently High and Increasing Drug
Prices, 29 AM. J.L. & MED. 525 (2003) (describing the easy substitution of counterfeit drugs
both for original pharmaceuticals as well as generics).
81. See Fritch, supra note 35, at 199 (citing COUNCIL ON SCIENTIFIC AFFAIRS AND
PUBLIC HEALTH, AMERICAN MEDICAL ASSOCIATION, FEATURED REPORT: GENERIC DRUGS,
June 2002, available at http://www.ama-assn.org/ama/no-index/about-amall 5279.shtml).
82. See generally CENTER FOR DRUG EVALUATION AND RESEARCH, FOOD AND DRUG
ADMIN., GUIDANCE FOR INDUSTRY BIOEQUIVALENCE RECOMMENDATIONS FOR SPECIFIC
PRODUCTS (2010), available at
http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatorylnformation/Guidances/u
cm072872.pdf.
83. See infra Part IV.C. But see McGough, supra note 75, at 261.
84. 35 U.S.C. § 156 (1988).
311
312 SANTA CLARA COMPUTER & HIGH TECH. L.J. [Vol. 27
trials to begin sooner than in the past and for generics to be off and
running when the patent for the pioneer drug expires.85 Consistent
with these public policy goals, allowing the same color and shape
would assist generics in competing against the pioneer drug
companies. Rejecting this argument, at least one court has recognized
that a simple doctor's explanation could alleviate any confusion or
anxiety regarding generic substitution, and that when doctors or
pharmacists explain that the generic drug is the same as the original,
patients generally accept it.86
As an argument against allowing generic drugs to use the same
shape and color, pioneer drug companies might contend that Hatch-
Waxman and other factors already assist generic drug companies'
ability to compete in the marketplace.8 7 Additionally, the pioneer
drug company was the one who invested in the research and
development for the pharmaceutical,88 much of which usually does
not lead to a marketable drug. To support the progress of science and
useful arts,89 some compromise should be reached to continue some
protection through the identifying function of pill shape and color.
The generic drug company may counter that the pioneer drug
company already received this protection through its patent. Indeed,
one potential downside of extending trade dress protection beyond the
life of the patent is that doing so could upset the balance between the
limited monopoly of owning a patent and the potentially perpetual
protection of trademark.
85. See H.R. REP. No. 98-857, pt. 2, at 5 (1984).
86. See Ives Labs., Inc. v. Darby Drug Co., 638 F.2d 538, 544-45 (2d Cir. 1981)
(judgment reversed by Inwood Labs., Inc. v. Ives Labs., Inc., 456 U.S. 844 (1982).
87. Prior to 1984, when Hatch-Waxman passed, generics were less than four percent of
total prescriptions in the United States. As of 2006, that number exceeded fifty-three percent.
See Fritch, supra note 35, at 172 (citing Examining the Administration's Proposed Health
Security Act, To Establish Comprehensive Health Care for Every American: Hearings Before
the S. Comm. on Labor and Human Resources, 103d Cong. 181 (1993) (statement of Lodewijk
de Vink, President and CEO, Warner-Lambert Co.)); Increasing Generic Drug Utilization:
Saving Money for Patients: Hearing Before the Subcomm. on Health of the H. Comm. on
Energy and Commerce, 109th Cong. 10 (2005) (statement of Kathleen Jaeger, President and
CEO, Generic Pharmaceutical Association), available at http://energy-
commerce.house.gov/108/Hearings/05182005hearingl 526/Jaeger.pdf).
88. See id. at 173 (citing PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF
AMERICA (PHRMA) PHARMACEUTICAL INDUSTRY PROFILE 2006, 2, 45 (2006), available at
http://phrma.org/files/20061ndustryProfile.pdf).
89. U.S. CONST. art. I., § 8, cl. 8.
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IV. APPLICATION OF FUNCTIONALITY TO PILL COLOR AND SHAPE
Taking the general trademark principles and public interest
considerations previously discussed and applying them in an analysis
of the leading pharmaceutical cases, this next section will separate the
cases not by whether color and shape were protectable, but rather by
what aspect of the medication was at issue. What precisely made the
pharmaceutical functional (or not)? This section will separate federal
court and Trademark Trial and Appeal Board (TTAB) decisions into
categories relating to flavor, psychosomatic effect, dosage/patient
compliance, utilitarian function, arbitrary color/shape selection,
generic substitution, and genericide. Ultimately, this section will
conclude that color/shape related to psychosomatic effect, dosage,
utilitarian function or generic substitution generally have not been
protected by trade dress while color/shape arbitrarily selected
generally, but not always, have been protected.
A. Flavor and Colors that Indicate Flavor
In one of the first cases examining trademark protection for a
pharmaceutical product, the Supreme Court separated the use of
chocolate as an ingredient from the unfair trade practices of a
competitor. The Court held that the use of chocolate flavor was
permissible; whereas the competitor's trade practices of inducing
product substitution by druggists was not.90 The case, Warner v. Eli
Lilly, involved the products "Coco-Quinine" and "Quin-Coco." Eli-
Lilly produced Coco-Quinine and Warner and Co. produced Quin-
Coco. Eli-Lilly added chocolate as an ingredient to impart a
distinctive color, but also because it made the preparation more
palatable and it served as an effective suspension medium. 91 For these
reasons, the Court determined that the color and flavor did more than
identify the preparation and could not be monopolized. 92 Nonetheless,
Warner was enjoined because it had been attempting to expand its
market by showing druggists that it would be in their best interest to
substitute Warner's similar and lower-priced Quin-Coco for Eli-
Lilly's Coco-Quinine. 93
Similarly, in In Re N. V. Organon, the TTAB affirmed the
trademark examiner's denial of registration for an orange flavor in an
90. See Warner & Co. v. Eli Lilly & Co., 265 U.S. 526 (1924).
91. See id at 531.
92. See id. at 531-32.
93. See id. at 529-31.
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anti-depressant medication. 9 4 The examiner concluded that "the
orange flavor gives an orally administered pharmaceutical product a
competitive advantage, and that giving applicant exclusive rights to
the flavor would place competitors at a substantial competitive
disadvantage."95 The applicant argued that the orange flavor did not
make the product more effective or impact its cost or quality. 96it
asserted that the orange flavor was added for a distinctive quality, "to
distinguish its product rather than for its flavor." 97 Articles submitted
in the record suggested that flavor was important for compliance and
showed the prevalence of orange flavor in medications. 98 The Board
applied the Morton-Norwich factors and gave particular weight to the
fact that the applicant's promotional materials highlighted the
utilitarian advantages of the orange flavor, and ultimately determined
that the flavor was functional and, hence, could not be protected by
trade dress. 99
B. Psychosomatic Effect
In a decision issued between Eli-Lilly and In re Organon, the
Second Circuit extended functionality considerations and refused to
allow trade dress protection for the color pink of Pepto-Bismol
because it said that pink had a "psychosomatic effect." In Norwich
Pharmaceutical Co. v. Sterling Drug,00 the Second Circuit denied
Pepto-Bismol protection for its bright pink color. The Court
determined that the color was functional because it was "soothing" to
patients.o' Despite this functionality determination, there was
evidence that Sterling Drug selected bright pink for its product,
Pepsamar, to mimic Pepto-Bismol. 102 Nonetheless, the court reasoned
that there was a "difference between a deliberate attempt to deceive
94. In re N.V. Organon, 79 U.S.P.Q.2d 1639 1650 (T.T.A.B. 2006).
95. Id. at 1641.
96. See id.
97. Id.
98. The record cited an article stating that kids like strange flavors, such as "blue
raspberry," whereas adults prefer citrus flavors like lemon, orange, and honey. Id. at 1642.
99. Id. at 1645.
100. Norwich Pharmacal Co. v Sterling Drug, Inc., 271 F.2d 569 (2d Cir. 1959).
101. Id. at 573.
102. The color was intentionally selected to build upon the goodwill that had been
established by Norwich Pharmacal's Pepto-Bismol product. If pink is the only color with a
soothing effect, then the functionality argument makes sense. However, Sterling Drug could
have selected a different color with a similar soothing effect that would not have relied upon the
market power of Pepto-Bismol. Id.
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and a deliberate attempt to compete."l 0 3 In this case, according to the
Second Circuit, Sterling Drug was trying to compete.10 4
An extension of this argument, not yet posed in any cases, is that
color possesses a certain inherent quality, and hence one company
should not be permitted to monopolize that color because it would
limit the competitiveness of other companies. This argument is based
more upon aesthetic functionality than traditional utilitarian
functionality. For example, studies have shown that blue is thought to
be a masculine color, hence the blue color for Viagra. 05 The market
acceptance would be much different for a pill for erectile dysfunction
that was bright pink. Similarly, studies have shown that purple is
thought to be a regal and dignified color, potentially a good choice for
an acid reflux drug.' 06
C. Patient Compliance; Color/Shape Indicates Dosage
The selections of palatable flavors and colors that have a
psychosomatic effect have been linked to another reason where courts
have found functionality: patient compliance. In the flavor cases,
patients, especially children, were more likely to take their medication
if it tasted good. 0 7 In the Coco-Quinine/Quin-Coco case, the
chocolate flavor and color was chosen in part because it was believed
that patients would take a medicine that tasted like chocolate. 08 In the
Pepto-Bismol case, if pink were perceived as soothing, then it made
the color more desirable and consumers would use the medication.'09
Sometimes the kind of ailment seems to have influenced courts
when they are assessing functionality in support of patient
compliance. For example, the orange-flavored medication in In re
Organon was an anti-depressant." 0 The Board may have been
influenced by the general unwillingness of depressed patients to be
compliant with taking their medications and this seemed relevant to
its functionality determination.'
103. Norwich, 271 F.2d at 572.
104. Id.
105. See Fritch, supra note 35, at 182 (citing Charles W. Schmidt, Have I Got a Drug for
You!, MODERN DRUG DISCOVERY, Dec. 2001, at 41, available at
http://pubs.acs.org/subscribe/journals/mdd/v04/il2/html/12money.html).
106. Id. at 182.
107. In re N.V. Organon, 79 U.S.P.Q.2d 1639, 1641-42(T.T.A.B. 2006).
108. Warner, 265 U.S. at 529, 531.
109. Norwich 271 F.2d at 526.
110. In re N. V. Organon, 79 U.S.P.Q.2d at 1640.
111. See generally In re N.V. Organon, 79 U.S.P.Q.2d. 1639
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Patient compliance also seemed to influence the Third Circuit in
Shire v. Barr Laboratories,112 where the patients had attention deficit
hyperactivity disorder (ADHD). In Shire, the court admitted
testimony as to why the color coding was important to ADHD
patients:
[B]ecause ADHD patients overuse visual cues, (1) when
therapeutically equivalent ADHD products have similar visual
recognition properties, adult ADHD patients will experience less
confusion in correctly identifying the agent and/or its dosage
strength; (2) given that almost all patients required some initial
dosage titration and a subsequent substantial majority required
intermittent dosage adjustment, the color coding of a particular
preparation of mixed amphetamine salts tablets confers a
substantial degree of clinical functionality for the patient in the
titration/adjustment process; (3) many adult patients may take
multiple daily dosages of different strength amphetamine salts
tablets, also inferring the usefulness of similar color-coding." 3
The patient compliance in Shire was also linked to the fact that the
medication, Adderall, came in two different dosages with colors and
shapes to indicate the strength. Originally the pills came in two
dosages and two colors: 10 mg. (blue/round) and 20 mg.
(orange/round).114 At the time of the dispute there were seven
variations, all indicated by size and color: 5 mg. (blue/round); 7.5 mg.
(blue/oval); 10 mg. (blue/round); 12.5 mg. orange/peach, round); 15
mg. (orange/peach, oval); 20 mg. (orange/peach, round); and 30 mg.
(orange/peach, round)." 5 The tablets were scored and had "AD"
stamped on one side and the dosage stamped on the other." 6
Although the colors and shapes may have been arbitrarily selected,
their color and shape were indicative of a particular dosage, with up
to seven variations for the ADHD patients, thus making the color in
combination with the size and shape of the pills functional according
to the court."
D. Color/Shape Serve a Utilitarian Function
These cases compare to more traditional utilitarian functions,
such as the pills in Smith Kline & French Laboratories v. Clark &
112. Shire U.S., Inc. v. Barr Labs., Inc., 329 F.3d 348 (3d Cir. 2003).
113. Id. at 354.
114. Id. at 350.
115. Id.
116. Id.
117. See id. at 352.
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Clark."' In Clark, the Third Circuit agreed that the pills were
functional, although the court ultimately supported its determinations
under unfair trade practices. The functional features of the pills
recognized by the court included the scoring and shape of the edges
and the color. 120 The scored design allowed for easier breaking of the
pills and the edges kept the pills from crumbling. 12 1 The pills' color,
white, was the natural color of the compound. 122 To change the color
would require an additional manufacturing step. It is easy to see how
these features serve utilitarian functional purposes and that the
manufacturer should not be permitted to monopolize these
characteristics.
E. Arbitrary Combination of Color and Shape
When color and shape have been arbitrarily selected and
marketed, however, courts have generally upheld the selection and
permitted trade dress protection. 123 In Ross- Whitney v. Smith Kline &
French Laboratories,124 one of the earlier pill color cases, the Ninth
Circuit upheld protection for heart-shaped pills in orange and pink.
Smith, Kline & French (SKF) had patents on benzyl methyl
carbinimine, which it marketed under the trademark "Benzedrine,"
and dextro-amphetamine sulfate, which it marketed under the
trademark "Dexedrine." 25 Initially SKF sold Benzedrine in a round,
white tablet, with beveled edges and a concave bottom. 12 6 It sold
Dexedrine in a similar shape in yellow. 127 A few months prior to
expiration of the patents, 12 8 SKF changed the colors of the pills to
pinkish-brown for Benzedrine and orange for Dexedrine. 12 9 It also
changed the shape to resemble a Valentine's heart. 130 From 1949 to
118. Smith, Kline & French Labs. v. Clark & Clark, 157 F.2d 725 (3d Cir. 1946).
119. See id. at 730-31.
120. Id. at 730.
121. Id.
122. Id.
123. See Bereskin, supra note 77, at 1087.
124. Ross-Whitney Corp. v. Smith Kline & French Labs., 207 F.2d 190 (9th Cir. 1953).
125. Id. at 191-92.
126. Id. at 192.
127. See id
128. Compare this patent in the compound to the patent for manufacturing the alleged
trade dress in the shredded wheat case. The patent in the compound enables the manufacturer to
copy the active ingredients. This does not necessarily lead to copying the trade dress as it did in
Kellogg.
129. Ross-Whitney, 207 F.2d at 192.
130. Id.
17
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1951, SKF spent in excess of $1.2 million to advertise the new shape
and color.' 3 ' In 1951, Ross-Whitney, doing business as the Heart
Pharmaceutical Co. of California, produced a dextro-amphetamine
sulfate pill, in the same shape and color as Dexedrine, and advertised
it as "Heart Brand Dexedrine."1 32
The district court determined that Dexedrine was marketed "in a
unique, distinctive, non-functional, well-advertised color and shape
combination which ha[d] acquired a secondary meaning."13 The
court also found copying, palming off by some pharmacists, which
was possible because of the counterfeit tablets, that Dexedrine was
not a generic name, and that some of the generic pills were not of the
same potency as the original. The court concluded that "neither the
trademark Dexedrine nor the shape-color combination of SKF's
tablets [was] in the public domain"l34 and held that there had been
unfair competition. The Ninth Circuit upheld the district court's
determinations, reasoning that the there was clear evidence that the
shape and color were intended to identify SKF's Dexedrine.135
According to the Ninth Circuit, "[t]he wrong was in designedly
enabling the dealers to palm off the preparation as that of (SKF)." 36
Hence, SKF's unique shape and color were protected.
Similarly in Boehringer Ingelheim G.m.b.H v. Pharmadyne
Laboratories,'3 7 a district court upheld trade dress protection when
the color and shape were arbitrarily selected and not related to the
therapeutic effect of the medication.' 3 8 Boehringer marketed its pill,
Dipridamole, in small orange biconvex tablets for more than 15
years. 139 Boehringer had not selected the shape to be easier to break
or the color to represent a particular flavor or dosage.140 The only
differences between the competitor's pills were small logos imprinted
on the pills.141 Because Boehringer's trade dress was not functional
and the company proved secondary meaning, the court forbade
131. See id
132. Id.
133. Id. at 192.
134. Id. at 193.
135. See id. at 196. The court did not determine, "[w]hether or not the heart shape is
functional in that it prevents the tablet from rolling away when dropped." Id
136. Id. at 197 (citing William R. Warner & Co. v. Eli Lilly & Co., 265 U.S. 530 (1924)).
137. Boehringer Ingelheim G.m.b.H. v. Pharmadyne Labs., 532 F. Supp. 1040 (D.N.J.
1980).
138. See id. at 1057.
139. See id at 1056.
140. See id. at 1057.
141. See id. at 1045.
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Pharmadyne from copying the unique trade dress.14 2 Other examples
of successful arbitrary combinations of color and shape include the
little blue pill, Viagra,143 and the purple pill with yellow stripes,
-144Nexium.
F. Generic Substitution/Genericide
Courts have not always upheld trade dress protection of an
arbitrary selection of pill shape and color. In Marion Laboratories v.
Michigan Pharmacal,14 5 for example, a district court denied
protection for a clear and brown gelatin capsule. The drug at issue
was a vasodilator that originally was available only by tablet or
injection, which had to be administered every two hours. 146 The drug
fell into disuse until Marion decided to produce the drug in a
sustained-release form, requiring administration only every eight to
twelve hours. 147 The capsule itself was purchased from Eli Lilly and
Co. 148 Eli Lilly produced a color wheel demonstrating 12,000 possible
color combinations. Marion selected clear and brown for its capsule
and expended $2.5 million between 1970 and 1971 to advertise its
trademarked product, Pavabid.14 9
The defendant, Michigan Pharmacal, copied both the time-
release formula and the brown and clear capsule.15 0 Michigan
Pharmacal was not alone, as 30 to 40 other companies also began
distributing the vasodilator in brown and clear capsules."s' Thus, out
of the 12,000 color combinations possible, Marion's competitors,
including Michigan Pharmacal, all selected brown and clear
capsules. 15 2 Marion lost its case in part because it failed to prove
secondary meaning. 153 Although the court did not equate its
determinations to genericide, essentially that is what happened. Eli
142. See id. at 1067.
143. See, e.g., Meeting the Pharna Challenge, WORLD TRADEMARK REV. 52 (Nov./Dec.
2006), available at http://www.worldtrademarkreview.com (discussing international protection
for light blue and unique geometric shaped pharmaceuticals).
144. See generally Fritch, supra note 35 (noting that purple pill also has yellow stripes).
145. Marion Labs., Inc. v. Mich. Pharmacal Corp., 338 F. Supp. 762 (1972).
146. See id. at 768.
147. See id.
148. See id.
149. See id. at 764, 768.
150. See id. at 768.
151. See id.
152. See id.
153. See id. at 769.
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Lilly had spent $2.5 million dollars in one year on marketing, 5 4 and
normally this would support a finding of secondary meaning. 155 The
only reason that brown and clear was used by at least thirty others
was to copy and usurp the goodwill established by Marion. Marion's
efforts thus led to genericide of its brown and clear capsule as that
became the industry standard allowing others to trade off of Marion's
expenditures and goodwill.
Contrast the Marion case with the famous Smith, Kline, &
French v. Premo Pharmaceutical Laboratories5 6 case, where
competitors selected a variety of different color combinations. In
Premo, the plaintiffs maroon and white color combination also was
arbitrarily selected, yet its competitors chose other color
combinations. Premo, the producer of the generic form of the drug,
selected the same trade dress as SKF and entered testimony that
copying the color combination was desirable in the pharmaceutical
industry for identification of medications, to ensure proper
dispensing, and for rapid identification in emergency situations. 57
Other leading pharmaceutical manufacturers, however, sold different
drugs also in a maroon/white or dark red/white combination, thus
undercutting the argument for standardization.15 8 In addition, the
court reasoned that the color was not functional because the identical
drug combination as SKF's was successfully marketed in an orange
tablet.15 9 Therefore, the color combination was found not to be
functional, because it was arbitrarily selected, there were other
successful products with different colors in the same market, and
there were similar colors for pills for different medications.160
In one of the seminal drug cases, Inwood Laboratories v. Ives
Laboratories,'6' the Supreme Court considered whether the
manufacturer of a generic drug, which copied the appearance of a
competitor's drug, could be held vicariously liable for pharmacists
who mislabeled the generic drugs with the competitor's registered
trademark. Ives had a patent on the drug cyclandelate, a vasodilator
154. See id. at 764.
155. See e.g., Deborah F. Buckman, Annot., When is trade dress "inherently distinctive"
for purposes of trade dress infringement actions under § 43(a) of Lanham Act (15 U.S. C.A.
§ 1125(a)) - Cases after Two Pesos, 161 A.L.R. FED. 327 (2000) (collecting cases).
156. SK&F v. Premo Pharm. Labs., Inc., 625 F.2d 1055 (3rd Cir. 1980).
157. See id. at 1060.
158. See id.
159. See id at 1064.
160. See id. at 1063.
161. Inwood Labs., Inc. v. Ives Labs., Inc., 456 U.S. 844 (1982).
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intended for vascular diseases. It sold the drug in blue capsules with
"Ives 4124" imprinted for the 200 mg. dosage and blue/red capsules
imprinted with "Ives 4148" for the 400 mg. dosage.' 6 2 When the
patent expired, several generic drug manufacturers began marketing
the generic version of Ives' "Cyclospasmol" in the same color
combinations.163 Some pharmacists mislabeled and dispensed the
generic drugs as Cyclospasmol.16 4
Ives argued that the colors were not functional and that they had
acquired secondary meaning.16 5 More importantly, they argued "that
pharmacists would continue to mislabel generic drugs as
CYCLOSPASMOL so long as imitative products were available."l 6 6
Denying Ives' claims and its request for injunctive relief, the Court
determined that the court of appeals erred when it rejected some of
the district court's findings, which were not clearly erroneous.' 6 7
Among these were the district court's conclusions that the blue and
blue/red colors were functional because:
many elderly patients associate color with therapeutic effect; some
patients commingle medications in a container and rely on color to
differentiate one from another; colors are of some, if limited, help
in identifying drugs in emergency situations; and use of the same
color for brand name drugs and their generic equivalents helps
avoid confusion on the part of those responsible for dispensing
drugs. ... In addition, because Ives had failed to show that the
colors indicated the drug's origin, the court found that the colors
had not acquired a secondary meaning.168
In addition to the policy considerations, the plaintiff had failed to
prove secondary meaning.' 69 Although the Court did not mention it
explicitly, part of their reasoning for pill identification may have been
influenced by the fact that the pills were blue or a combination of red
and blue, which could have aided in identifying a heart medication.
This is also a situation where different colors represented different
dosages.
In another generic substitution case, American Home Products v.
162. Id. at 846-47.
163. Id. at 847.
164. See id, n.4.
165. Id. at 850-51.
166. Id. at 851.
167. See id. at 855-58.
168. Id at 853.
169. Id.
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Barr Laboratories, 70 a district court found that there was no
likelihood of confusion between plaintiffs trademarked Advil
product and defendant's generic ibuprofen. The court compared the
two pills and although they were similar in color, the defendants
argued that they differed in shape, surface finish, and labeling."17
The court noted that the color, shape, sheen, and label of Advil,
presented an overall "'high style' 'high design,' perhaps even 'high
tech,' look ... " The generic ibuprofen, in contrast, was more of a
flat brown.173 It was thick like traditional aspirin, rather than convex
like Advil.17 4 It was not shiny like Advil and its mark was stamped,
rather than printed on the pill.175 The court concluded that the
consumer would not likely be confused given these differences in
appearance. 176 Unlike in the prescription cases where sometimes the
only distinguishing feature is the color and/or shape of the
pharmaceutical, this over-the-counter drug also had distinguishing
boxes, bottles, labels and promotional materials.' 77
V. PROPOSED SOLUTIONS/REGULATORY OPTIONS
Taking these various court decisions and public interest concerns
into account, following are a list of suggestions for regulating pill
shape and color.
A. Color/Shape Should Not Become Functional by Genericide
as a Result of Creating Secondary Meaning
In the non-trade dress context, genericide will occur when the
trademark comes to be associated with the genus, rather than the
species, of a product.' 78 However, for color, shape and product
design, the owner must extensively advertise and promote its product
to create the secondary meaning.17 9 It seems that the more successful
the product, then, the more likely that it will become "generic" in the
170. American Home Prods. Corp. v. Barr Labs., Inc., 656 F. Supp. 1058 (D.N.J. 1987).
171. Id at 1064.
172. Id. at 1063.
173. See id at 1064.
174. See id.
175. See id.
176. See id at 1068.
177. See id. at 1068-69.
178. See A.J. Canfield Co. v. Honickman, 808 F.2d 291, 298 (3d Cir. 1986).
179. See generally David E. Rigney, Annotation, Application ofsecondary meaning test in
action for trade dress infringement under § 43(a) of Lanham Act (15 U.S. CA. § 1125(a)), 87
A.L.R. FED. 15 (1988).
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mind of consumers, as it did in the Ives case.180 It has been argued
that this popularity should be a reason to award the particular
protection for the shape or color because it can support secondary
meaning, rather than allow it to be a means for genericide.18 1
Furthermore, it has been argued that when a color and/or shape are
arbitrarily selected to indicate the source, there should be no finding
of functionality. 182 This article supports these arguments.
Although not directly addressed in case law, the reality is that
when owners are investing enough resources in the marketing of their
product to create an association in the minds' of the public, then the
color/shape begins to assume a meaning other than just identifying the
source of the good. This sort of genericide potentially leads to a
finding of functionality by some courts and an exclusion of protection
of otherwise acceptable trade dress. As argued below, if the color and
or shape were to become functional or generic because it is accepted
as the industry standard, then the FDA should set this standard, not
generics that enter the market with the same design as the pioneer.
The Marion and Ives cases represent the scenario where a
pharmaceutical color and/or shape become functional after the period
of use necessary to create secondary meaning.' 83 In Marion, several
competitors free-rode on Marion's goodwill and adopted the same
color scheme.184 In the Ives case, patients had come to associate the
drug color and shape with its therapeutic effects and Ives was unable
to establish secondary meaning. 85 The consumers recognized it as a
heart medication, rather than as the particular pharmaceutical or as
being associated with a particular manufacturer. As the plaintiff
argued in Ives, it is the similarity of the medications that make illegal
substitution and unfair competition practices even possible.18 6 "It was
the manufacturers' use of capsules identical in size, shape, and color
180. See 3 CALLMANN, supra note 40, § 19:8.
181. See McGough, supra note 75, at 256-57. "[W]ith a few possible exceptions, the
protectibility of prescription trade dress should not be analyzed in terms of functionality." Id.
Instead, McGough contends, the analysis should focus on whether the trade dress actually is
generic. See id.
182. See Karl, supra note 75, at 367 (arguing that functionality should not act as a shield
when people intentionally pass of their goods). See also Bereskin, supra note 77, at 1087 ("In
the case of pharmaceutical get-ups, usually there is no utilitarian, cost or quality reason
sufficient to justify making a generic product look like the brand name product").
183. See Inwood Labs., Inc. v. Ives Labs., Inc., 456 U.S. 844 (1982); see Marion Labs.,
Inc. v. Mich. Pharmacal Corp., 338 F. Supp. 762 (E.D. Mich., S.D. 1972).
184. Marion, 338 F. Supp. 762.
185. Inwood, 456 U.S. 844.
186. See Karl, supra note 75, at 346.
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to 'Cyclospasmol,' together with the catalogs comparing the
appearances and prices of the two drugs, that amounted to 'suggestion
by implication.'" 187 Without the color and shape similarities, one
would question whether the unfair trade practices resulting with
illegal substitution would be as likely to occur.
To draw some contrasts with the Marion case, it seems illogical
that one company (Marion) should be penalized for its success and
the fact that its arbitrarily selected color combination was copied,
while another company (SKF) should be rewarded because there were
some competitors who did not copy its color combination. Defendant
Premo was in the same position as defendant Michiganl 89-both
copied the color combinations and attempted to ride on someone
else's goodwill and marketing efforts. Yet, in Marion,190 a form of
genericide took place, while in Premol9' it did not.
Even in Shire, there was some blurring between secondary
meaning and functionality. As David Fritch notes in his article,
"Should 'The Purple Pill' by any other Drug Company still be as
Purple? The Changing Face of Trade Dress Protection for
Pharmaceutical Manufacturers:"
The very elements of Shire's trade dress that the Shire court found
to give the color scheme functionality, however, are the source of
the scheme's secondary meaning and trademark protection. ... In
the case of generic drugs, any therapeutic benefit derived from the
familiarity of a pill's color is because the brand name manufacturer
created secondary meaning in their pill's color scheme.
When a patient takes a generic drug that looks identical to its
brand-name counterpart, the purported 'therapeutic benefit' from
the identical color scheme is derived from the patient's strong
association between the pill's color and its perceived source.192
Hence, the function of the pill actually resulted from the
patients' perception that they were taking the prescription drug
Adderall, rather than the active ingredient shared with the generic
drug.193 This functionality is then linked to the purpose of requiring
development of secondary meaning, and usually afforded benefit for
187. Id. at 365 (quoting Ives, 638 F.2d at 542).
188. SK&F v. Premo Pharm. Labs., Inc., 625 F.2d 1055 (3rd Cir. 1980).
189. Marion, 338 F. Supp. 762.
190. Id.
191. SK&F, 625 F.2d 1055.
192. Fritch, supra note 35, at 195.
193. See id.
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this success. "The Shire Court, however, found the elements of
secondary meaning to be a functional characteristic and grounds for
denying protection for Shire's trade dress." 94
Furthermore, as Daniel Bereskin argues in his article on look-
alike drugs, "it surely must also be the case that patients, who have
relied upon a medication for many months or years, including patients
who associate the [trade dress] with a particular medicine, believe that
the medicine comes from a particular source and they have learned to
trust that source."l 95 The patients make an association that is a result
of the effort expending to acquire secondary meaning or from long-
time use of a particular drug. They associate the drug with the source
that they have come to expect, even if the trade dress also signifies a
particular kind of drug to them. The fact that the trade dress indicates
a single source should be enough to afford protection.196
B. Generic Substitution Should Not Be a Reason for
Color/Shape to Be Functional
Nonetheless, the argument could be made that generic
substitution and patient acceptance of generics should be a reason to
allow substitution of confusingly similar color and shape. After all, it
furthers the goals of the Hatch-Waxman Act.19 7 However, intentional
confusion runs counter to the Lanham Act.'9 8 If we are to provide
trade dress protection at all, then we should require differences in
appearance. Consumers have the right to know that a generic drug is
actually provided by a different manufacturer and allow them to
choose the lower-priced option, rather than forcing compliance by
presenting them with confusing trade dress.' 99 This is particularly
important in prescription drugs where packaging and other features
that might eliminate confusion are no longer present.
For example, part of the problem in Ives was that the district
court had determined that there was no secondary meaning because
Ives had failed to show that the colors indicated the drug's origin.200
194. See id.
195. Bereskin, supra note 77, at 1092.
196. See Aaron M. Pile, What's in Your Bottle? Shire US Inc. v. Barr Laboratories Inc.
and its Effect on Prescription Drug Trade Dress Protection in the Third Circuit, 5 U. Pirr. J.
TECH. L. POL'Y 1, 2 (2005).
197. See 35 U.S.C. § 156 (2006).
198. See 15 U.S.C. § 1125(a) (2006).
199. See Bereskin, supra note 77, at 1087 (arguing that trade dress is an important aspect
of a patient's right to choose the source of his medicine).
200. Inwood Labs., Inc. v. Ives Labs., Inc., 456 U.S. 844, 853 (1982).
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The same issue arose in Shire.2 0 1 One reason that a drug may not be
associated with its source might very well be because generic drugs
are allowed to enter the market with the same color scheme.
Consumers would not expect a particular color scheme, even one that
is arbitrarily selected and not affiliated with dosage, to be associated
with a particular manufacturer if anyone can enter the market with the
same trade dress. If the feature is a generic one, like the chocolate
dipped cookies, or if the patent had dictated the shape and color, like
the shredded wheat, had expired, then the situation would be
different.
In pharmaceuticals, however, there is a self-fulfilling prophecy
that drug color is associated with the genus of medication, not the
species or the source. For example, a company expends money to
gain market share and identifiable trademarks and trade dress. As
soon as competitors can enter the market, they intentionally adopt the
same trade dress and confuse consumers. Consumers thus begin to
associate the trade dress with the kind of medication (the genus), not
the source (the species).202 No secondary meaning is found despite the
fact that the only reason that there is an association is due to the
investment by the pioneer company to create the association in the
minds of the consumers.
Furthermore, the secondary meaning and functionality are now
blurred (not to mention genericide) and the trade dress is "functional"
because it now represents a type of medication. The effort that was
required to gain protection now negates that same protection. If this is
a desired result, then the shape and color of a drug should be
regulated by the FDA along with the generic approval process, rather
than by applying circular reasoning for secondary meaning and
functionality and blurring these with the parallel purpose of
genericide.
C Functionality Should Be Determined When Adopted
At a minimum, functionality should be clearly removed from
secondary meaning and could be determined at the time that it is
adopted.2 03 A manufacturer can thus still use the traditional methods
to prove that it has acquired secondary meaning in the marketplace. If
201. Shire U.S., Inc. v. Barr Labs., Inc. 329 F.3d 348, 358 (3d Cir. 2003).
202. See Bereskin, supra note 78, at 1087 (arguing that allowing generic imitation actually
leads to consumer confusion).
203. See Pile, supra note 196, at 8 (arguing that functionality should play less significant
role in determination of trade dress infringement and also lessening role of distinctiveness).
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the functionality determination were made at the time that the trade
dress were adopted, then it would not get confused with this
analysis-the color would not become "functional" over time. This is
the inverse of Callmann's statement in his treatise's section on
functionality: "In the case of functional features ... they do not lose
their functional character despite the acquisition of secondary
meaning, or even despite any inherent distinctiveness. Competitors
still have the same legitimate need to employ [the feature] for their
functional advantages." 204 Likewise, a feature should not acquire
functionality because it has acquired distinctiveness.
At the time that a color, shape, or flavor is adopted it either
serves a functional purpose or it does not. The orange and chocolate
flavors were functional when they were adopted because they made
the medication more palatable. The seven different color/shape
schemes for the ADHD medication were functional when they were
adopted because they indicated the relative dosage, not just the
manufacturer. The brown and clear capsules, the blue capsules, the
blue and red capsules, the maroon and white capsules, all served no
functional purpose when they were adopted. It would be the
manufacturer's separate burden in those cases to show that they had
acquired secondary meaning, but at least that determination would not
be blurred with an assessment of functionality and generic
substitution.
Similarly aesthetic functionality should be determined at the time
that an appearance is chosen. A color and shape that is arbitrarily
selected does not add to the aesthetic of the product. The consuming
public does not purchase a pharmaceutical necessarily because they
like the color or shape of the product, but rather because they
recognize it. After extensive advertising campaigns, consumers
recognize "the purple pill" or the "little blue pill." These features do
not necessarily make the product more desirable or attractive to the
consumer; they merely make the product more memorable in the
minds of consumers. This is not a non-reputational need; it is a
reputation-related need. As the Ninth Circuit has stated the
distinction: "A feature which gives the consumer a substantial reason
for purchasing the product, as opposed to merely to distinguishing it
from other products, is functional. By contrast, if a feature serves
primarily to identify a product and does not contribute substantially to
the product's value, as determined by consumers, it is non-functional
204. 3 CALLMANN, supra note 40, at § 19:7.
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and may not be copied." 20 5 The generic company or other competitor
wants to build upon the reputation of the pioneer company to be able
to compete; this is not the same thing as aesthetic functionality.
D. Industry Standards and Generic Use of Color/Shape Should
Be Regulated by the FDA, Not Courts or the USPTO
Ultimately, courts and the USPTO are not the proper venues to
determine the functionality of colors and shapes for
pharmaceuticals.206 The authority more properly rests with the
FDA.207 In error medication testing, for example, the FDA's focus is
"not on commercial rights, but on the risk of medication-dispensing
errors." 208 This focus would be appropriate to make objective
determinations regarding color and shape. These objective
determinations would then lead to commercial implications, but not
necessarily be made because of them.
In fact, the FDA already has a procedure in place for approval of
trademarks on pharmaceuticals. 209 This procedure could be extended
to include an assessment of trade dress color and shape. When the
color and shape are adopted, the FDA could determine whether they
are functional and make the parallel determination whether they
should become the industry standard due to the psychosomatic effect
of the particular color, the need to distinguish between a variety of
dosages, or the suggestion that the color represents a particular kind
of medication. If the color, color combination and/or shape are
arbitrarily selected, however, the FDA will likely not determine that it
should be the industry standard and the pioneer company then still
would have the burden to develop and prove secondary meaning. If
the pioneer company knows from the beginning that the color or
combination will become the industry standard, then it might decide
to invest fewer resources in marketing those features.
In the FDA, the Center for Drug Evaluation and Research
205. Famolare, Inc. v. Melville Corp., 472 F. Supp. 738, 743 (D. Haw. 1979).
206. See Karl, supra note 75, at 366 (stating, "It is difficult to conclude that color can be a
functional attribute of a drug capsule or tablet in the absence of a universal color identification
standard.")
207. See, e.g., Bereskin, supra note 77, at 1102. Footnote 14 in Bereskin's article, id. at
1089, notes that there was an initiative launched prior to 1984 in the United States for the FDA,
but it was rejected because appearance was not closely enough related to safety or effectiveness.
If this is the case, then should compliance and patient safety be arguments for functionality? If
there are no safety or effectiveness concern for FDA to regulate, then shouldn't this be a basis
for supporting functionality and substitution?
208. Thomas, supra note 74, at 326.
209. See 3 McCarthy, supra note 31, at § 19:149
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(CDER) has transferred the authority for reviewing proposed
pharmaceutical trademarks to the Division of Medication Errors and
Technical Support (DMETS) of the Office of Drug Safety (ODS).2 1 0
"DMETS's purpose is to minimize medication errors resulting from
trademarks for pharmaceuticals that look or sound like currently
marketed drug names, other medicinal products, or commonly used
medical abbreviations, medical procedures, and/or lab tests."21 1
During Phase II of clinical trials, companies submit proposed
package insert labeling, a visual representation of the proposed label,
including two possible trademarks. 2 12 The trademark is then reviewed
for name suitability (i.e. does it imply a clinical process unsupported
by clinical data or is it too similar to the generic drug name).2 13 When
reviewing the proposed trademark, the DMETS attempts to simulate
the prescription process to predict confusion.2 14 It uses input from
doctors, pharmacists, nurses, and other health care practitioners. 2 15
The name is tested for both the written and verbal prescription
216
process. The trademark undergoes a second review ninety days
prior to the formal approval of the drug to compare it to any
subsequently approved trademarks. 2 17 Even though the drugs may be
prescriptions, "the rule regarding a lesser degree of likelihood of
confusion for medicinal products should control over the suggested
'sophistication' of physicians and pharmacists."2 18 Furthermore, if a
prescription and a non-prescription drug have similar names, people
who self-diagnose may be misled into believing that they are
equivalent.219
Admittedly, the FDA evaluation of the trademark and a USPTO
evaluation serve different purposes: the DMETS considers whether
the trademark would be confused by health practitioners or
pharmaceuticals whereas the USPTO assesses confusion by anyone,
including consumers. 22 0 Accordingly, the FDA's standard of proof to
210. Seeid
211. Id.
212. See id.
213. See id.
214. See id.
215. See id.
216. See id.
217. See id.
218. See 4 MCCARTHY, supra note 31, § 23:32 (citing Glenwood Labs., Inc. v. Am. Home
Prods. Corp., 455 F.2d 1384 (C.C.P.A. 1972).
219. See id. (citing Eli Lilly & Co. v. Natural Answers, Inc. Inc., 233 F.3d 456, 56
U.S.P.Q.2d 1942 (7th Cir. 2000).
220. See 3 MCCARTHY, supra note 31, § 19:150.
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show a likelihood of confusion with drug and pharmaceutical names
is different than that of the USPTO: the Lanham Act covers confusion
as to source as well as confusion between products.22 1
Despite the different concerns, it seems that if the confusion is
addressed at the source, when the drugs are approved by the FDA,
that this would limit the permissibility of pharmaceuticals with
confusingly similar trade dress to enter the market. This is particularly
true with regard to generic drugs, despite the expedited process that is
accorded generic drugs to enter the market more quickly after Hatch-
Waxman.2 22 The USPTO and courts could then serve as a backstop
for broader consumer likelihood of confusion and secondary meaning
concerns. The DMETS is already in place to assess the likelihood of
confusion between pharmaceuticals for verbal and written confusion.
It would be a logical step to add sight for trade dress to this
assessment. Thus, if the color is not the industry standard, then the
pioneer would still need to invest enough to develop secondary
meaning. This would eliminate genericide, unless after the term of the
patent for the pioneer drug, the pioneer is unable to establish
secondary meaning. It would also eliminate the stretching of
functionality to extend beyond utilitarian and aesthetic functionality.
Accordingly, the FDA could determine when it would be
industry-accepted practice for color or shape to signify a particular
dosage or that the color has a unique psychosomatic effect. Whereas
examiners and judges have been influenced by the kind of ailment at
issue, the FDA would be in the best place to assess whether the
particular visual cues are necessary for compliance or whether the
shape and color that indicate a particular dosage should be accepted
as an industry standard.
E. No Trade Dress Protection for Flavor
Finally, colors that represent flavors or flavors themselves are
the one category where there are legitimate scarcity and utilitarian
functionality arguments and because trade dress protection should not
be available, no regulation is necessary. 22 3 This standard would be
consistent with non-pharmaceutical cases, such as Dippin Dots v.
Frosty Bites Distribution, where the Eleventh Circuit held that the
colors used in ice cream were functional because they suggested
221. See id. (citing KOS Pharma., Inc. v. Andrx Corp., 369 F.3d 700 (3rd Cir. 2004); see
also Thomas, supra note 74, at 326.
222. 35 U.S.C. § 156 (1984).
223. See 3 CALLMANN, supra note 40, § 19:8.
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particular flavors.2 24
For medicinal preparations and pills that dissolve, there are only
a few flavors that are competitive (i.e. palatable). A quick tour of the
over-the-counter section of the pharmacy reveals the popularity of
lemon, orange, grape, cherry, honey, and mint. As the Board
recognized in In Re Organon, certain flavors are more palatable to
consumers, such as citrus flavors for adults and berry flavors for
children. To allow manufacturers to corner a monopoly on these
flavors would have anti-competitive effects, such as the TTAB
determined in the Organon225 proceeding. If there is a flavor
associated with a particular medication, the functionality limitation
would naturally relate to the use of color to represent that particular
flavor, for example orange color to represent orange flavor.
CONCLUSION
"Unlike in other industries, several courts have denied protection
where it can be demonstrated that the product design serves any
useful purpose to the doctor or patient-including the ability to
distinguish the product from others in the marketplace."226 This useful
purpose is being called a functional feature, even when it does not fit
the traditional notions of utilitarian or aesthetic functionality.
My proposed solution is to clearly separate secondary meaning
and genericide from functionality so that they serve complementary
rather than opposing purposes. Accordingly, one possible solution is
to assess functionality at the time when the color/shape is adopted, not
at the time of assessing secondary meaning. In addition, if generic
drug companies or other competitors are allowed to use the same
trade dress as the pioneer company, then this determination should be
made by the FDA, not the courts or the USPTO. The FDA could also
determine industry standards for a particular medication rather than a
determination of genericide by the courts. In addition, the FDA could
make decisions regarding industry standards regarding acceptable
trade dress for dosage specifications.
Ultimately, a pill's shape or color should be determined to be
functional because it meets traditional definitions of utilitarian and
aesthetic functionality, not because a court determines that it is
224. Dippin' Dots Inc. v. Frosty Bites Distribution, LLC, 369 F.3d 1197, 1203-4 (11th Cir.
2004).
225. See 3 CALLMANN, supra note 40, § 19:8.
226. Julia Anne Matheson & Michael R. Justus, Eye Candy, MM&M, Apr. 2009, at 56,
available at http://media.haymarketmedia.com/documents/2/eye%20candy_1542.pdf.
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functional as a result of the effort expended to create secondary
meaning or that there is an "industry standard" because the second
comers have intentionally copied the pioneer.
